Loop electrosurgical excision procedure for biopsy-confirmed high-grade cervical dysplasia — from treatment indication through post-procedure surveillance
Cervical cancer screening abnormalities are graded on a spectrum. Colposcopy-directed biopsy provides the histologic diagnosis that determines management: low-grade cervical intraepithelial neoplasia (CIN1) reflects a productive HPV infection that frequently clears on its own and is usually observed, while high-grade disease (CIN2/CIN3) carries meaningfully higher risk of silent progression to invasive cancer if left untreated — and this distinction is the fulcrum of the entire management decision.
Cervical dysplasia is identified through a staged pathway rather than a single test:
• Primary screening: cytology (Pap test) and/or high-risk HPV testing flags patients for further evaluation • Colposcopy: magnified visual examination of the cervix, often with acetic acid application, to identify areas of abnormal-appearing epithelium • Directed biopsy: small tissue samples taken from the most abnormal-appearing areas provide the histologic diagnosis — this is what actually grades the lesion, not the screening test result alone
The biopsy result is reported using the CIN (cervical intraepithelial neoplasia) grading system, reflecting how much of the epithelial thickness shows abnormal, disordered cell maturation:
• CIN1: abnormal cells confined to the lower third of the epithelium — a low-grade finding • CIN2: abnormal cells extend to the lower two-thirds — an intermediate/high-grade finding • CIN3: full-thickness epithelial abnormality (including carcinoma in situ) — the highest-grade pre-invasive finding
Management decisions hinge on this grade, combined with patient-specific factors such as age, fertility plans, lesion size, and whether the entire transformation zone was visualized at colposcopy.
The rationale for differential management rests on natural history data accumulated over decades of longitudinal study:
Low-grade lesions (CIN1): • Represent the visible manifestation of a productive, transient HPV infection • A substantial proportion regress spontaneously as the host immune response clears the infection • Progression to higher-grade disease within observation windows is comparatively uncommon • Standard approach: surveillance with repeat cytology/HPV co-testing rather than immediate excision, avoiding unnecessary procedures
High-grade lesions (CIN2/CIN3): • Reflect a more established, less transient disease process with reduced likelihood of spontaneous regression • Carry a non-trivial risk of silent progression to invasive squamous cell carcinoma if left untreated over years • Because invasive cervical cancer is difficult to detect early and carries substantial morbidity, the calculus favors intervention • Exception: in select young patients desiring future fertility with CIN2 (not CIN3), a period of observation may be individualized — but CIN3 and persistent/progressive CIN2 generally proceed to treatment
This risk-stratified approach avoids overtreating self-limited infections while intervening decisively where the biology favors treatment.
The core clinical principle: histologic grade — not screening test result alone — drives the treat-versus-observe decision. High-grade dysplasia is treated because the balance of progression risk versus procedural risk favors excision; low-grade dysplasia is usually observed because spontaneous regression is common and unnecessary treatment carries its own downsides.
The Loop Electrosurgical Excision Procedure (LEEP), also called LLETZ (large loop excision of the transformation zone), uses a thin wire loop energized with high-frequency alternating current to cut through cervical tissue with minimal thermal spread. In a single controlled pass, the loop excises the entire transformation zone containing the lesion — accomplishing two goals simultaneously: therapeutic removal of the abnormal tissue and generation of an intact specimen that can be examined under the microscope.
The physical principle behind LEEP is controlled electrical current concentration:
• The wire loop is extremely thin, so current density at its edge is very high — this vaporizes tissue water at the point of contact, allowing the loop to pass through tissue almost like a hot knife, rather than crushing or tearing it • A dispersive return electrode (grounding pad) placed elsewhere on the patient completes the circuit, spreading the returning current over a large surface area so it causes no injury there • The generator alternates between a "cutting" waveform (continuous, lower voltage) for excising tissue and a "coagulation" waveform (pulsed, higher voltage) for controlling bleeding after the loop pass • The clinician selects a loop size and shape that will encompass the entire visualized lesion and transformation zone in one continuous, steady pass — multiple passes or a second smaller pass may be used to obtain extra endocervical tissue when needed
Because the thermal effect is concentrated at the loop edge and the pass is quick, the specimen's architecture is largely preserved — critical for the next step, pathologic evaluation.
Unlike ablative treatments (such as cryotherapy or laser vaporization) which destroy tissue in place and leave nothing to examine, LEEP is an excisional procedure — it produces a physical specimen. This is the central practical distinction: ablation cannot confirm what was removed, while excision (LEEP, cold-knife conization) can.
The choice of LEEP over ablative methods is driven by diagnostic certainty:
• Occult invasion risk: colposcopy and biopsy can occasionally underestimate disease severity — a small focus of invasive cancer can hide beneath or adjacent to a high-grade lesion. Ablative treatment would destroy this focus without ever detecting it • Specimen orientation: the LEEP specimen can be oriented (endocervical vs. ectocervical margin marked) so the pathologist can map exactly where any residual abnormality lies relative to the excision edges • Depth control: loop size and shape can be tailored to lesion location, balancing complete excision of endocervical extension against preserving healthy cervical stroma — important for future fertility and pregnancy outcomes • Same-visit result: many LEEP procedures are performed immediately following colposcopic diagnosis in a single visit ("see-and-treat"), reducing loss to follow-up compared to multi-visit pathways
Once the LEEP specimen reaches the pathology laboratory, it is inked to preserve orientation, serially sectioned, and examined microscopically. The single most consequential finding reported back to the clinician is margin status: whether the abnormal epithelium extends all the way to the cut edge of the specimen (positive/involved margin) or stops well short of it (clear/negative margin). This one data point substantially shapes the entire post-treatment plan.
The excised cone-shaped or disc-shaped specimen is handled with care to preserve information:
• Orientation marking: the clinician or pathologist inks or sutures a reference point (commonly the 12 o'clock position) so the specimen's relationship to the cervix is not lost • Ink application: distinct colored inks are applied to different margins (ectocervical, endocervical, deep/stromal) before sectioning, so that under the microscope, ink touching abnormal cells identifies exactly which margin is involved • Serial sectioning: the specimen is cut into thin parallel slices (like a loaf of bread) and each slice is mounted, stained, and examined for the highest grade of abnormality present and its relationship to the inked margins • Reporting: the pathology report states the highest-grade lesion identified (e.g., CIN3), and specifically comments on whether each margin is free of disease or involved by it
A margin is called "positive" or "involved" when abnormal (dysplastic) cells are seen at the very inked edge of the tissue — meaning it cannot be excluded that abnormal tissue was left behind in the patient.
Margin status is not simply a pathology curiosity — it directly informs the follow-up strategy:
Clear (negative) margins: • Indicates the excision likely captured the entire lesion with a rim of normal tissue around it • Residual disease risk is comparatively low • Standard post-treatment surveillance testing is generally sufficient — no immediate repeat procedure needed
Positive (involved) margins, particularly the endocervical margin: • Does not automatically mean disease was left behind — some patients with positive margins have no residual disease on subsequent testing, as the excisional and healing process itself may eliminate residual abnormal cells • However, the risk of residual or recurrent high-grade disease is meaningfully elevated compared to clear margins • Management options considered: closer-interval follow-up testing (rather than immediate repeat surgery), or in select circumstances a repeat excisional procedure — the choice depends on which margin is involved, the grade of disease, and patient-specific factors
Endocervical margin involvement carries particular attention because residual disease there is harder to visualize on subsequent colposcopy, as it may be tucked inside the endocervical canal.
Margin status functions as the single most important prognostic marker generated by the LEEP procedure — it recalibrates the entire subsequent surveillance plan, shifting a patient from routine-interval testing toward closer-interval follow-up (or occasionally repeat treatment) when margins are involved.
After the loop pass, the cervix is left with a shallow surgical defect that must re-epithelialize — a process that unfolds over several weeks. During this healing window, patients are counseled on what bleeding and discharge to expect as normal, and which activities to avoid until the cervix has adequately healed, to reduce the risk of bleeding, infection, or disruption of the healing surface.
Immediately after LEEP, the excision site is treated with a coagulating agent to control surface bleeding, and the cervix begins its natural repair process:
• Days 1–7: light bleeding or spotting is common; some watery, blood-tinged, or brownish discharge is expected as the coagulated surface is shed • Weeks 1–3: discharge gradually lightens; a squamous epithelium begins to regenerate across the excision bed, migrating inward from the wound edges • Weeks 3–6: full re-epithelialization is typically complete; the cervix regains a normal-appearing surface, and the previously exposed stroma is covered
A small amount of delayed bleeding (sometimes 1–2 weeks after the procedure) can occur as the coagulated eschar separates from the healing bed — patients are counseled that this is usually self-limited, but heavier bleeding warrants clinical evaluation.
Until the cervical surface has re-epithelialized, the wound bed is more vulnerable to disruption and infection, which is why standard post-procedure counseling includes:
• Pelvic rest: avoiding vaginal intercourse for the recommended healing window, since mechanical friction can disrupt the fragile regenerating epithelium and provoke bleeding • No tampon use: tampons are avoided in favor of pads during the expected discharge period, reducing the risk of introducing infection or mechanically irritating the healing site • No douching: douching can disturb the healing surface and normal vaginal flora, and is avoided during recovery • Activity modifications: strenuous exercise or heavy lifting may be limited short-term per clinician guidance, as increased intra-abdominal pressure and pelvic blood flow can theoretically provoke bleeding • Follow-up visit: a post-procedure check (commonly around 4–6 weeks) confirms adequate healing before activity restrictions are lifted
These precautions are time-limited — once re-epithelialization is confirmed, normal activity resumes.
Post-procedure counseling emphasizes that light bleeding and watery discharge for one to a few weeks is an expected part of normal healing, not a sign of a complication — but patients are advised to contact their clinician for heavy bleeding, fever, or foul-smelling discharge, which can indicate infection or delayed healing.
A successful LEEP with clear margins substantially reduces — but does not eliminate — future risk. Patients who have been treated for high-grade cervical dysplasia remain at somewhat elevated risk of recurrent or new high-grade disease compared to the general screening population, even years after an apparently complete excision. This is why post-treatment surveillance follows a closer-interval schedule than standard population-based screening, rather than simply reverting to routine screening intervals.
Several biological realities explain why surveillance intensity remains elevated after treatment:
• Field effect: HPV infection and the dysplastic changes it produces are not always confined to a single, sharply demarcated spot — the broader lower genital tract mucosa has been exposed to the same infection, so new lesions can arise at sites distinct from the original excision • Persistent HPV infection: excision removes the visible lesion, but the causative high-risk HPV infection may persist in surrounding tissue in some patients, maintaining ongoing risk of new dysplastic change • Occult residual disease: even with clear margins, microscopic residual disease is possible in a minority of cases, as pathologic margin assessment samples the specimen rather than guaranteeing zero residual cells beyond the visible edge • Positive margins compound this risk further, which is why closer-interval testing (or repeat treatment in select cases) is recommended when margins are involved
Collectively, these factors mean that a history of treated high-grade dysplasia is itself a risk factor that outlives the procedure — it does not reset a patient to average population risk.
Rather than a single follow-up visit, post-treatment monitoring is structured as an extended surveillance program:
• Early post-operative visit: confirms healing and may include an initial assessment before formal surveillance testing begins • Co-testing at closer intervals: cytology combined with high-risk HPV testing is repeated at intervals shorter than routine population screening, since a persistently negative co-test over time is the strongest reassurance that treatment was successful • Extended duration: closer-interval surveillance typically continues for an extended, multi-year period after treatment before a patient can transition back to routine-interval screening — reflecting that risk, while declining over time, does not disappear immediately • Escalation triggers: any abnormal result during the surveillance window (abnormal cytology or a positive HPV test) typically prompts repeat colposcopy rather than simply repeating the test at the next interval • Long-term perspective: even patients who ultimately return to routine screening intervals are often counseled that their personal risk profile remains modestly elevated relative to someone who never had high-grade dysplasia
This structured, closer-interval approach is what allows high-grade dysplasia to be treated effectively as an outpatient procedure while still catching the minority of recurrences early, when they remain highly treatable.
The overarching principle of post-treatment care: successful LEEP with clear margins meaningfully lowers risk, but treated patients are managed as a distinct, higher-risk surveillance population for years afterward — not simply discharged back to standard screening the way an average-risk patient would be.